Radiolabelled analogues of
Somatostatin (SRIF) were demonstrated to be useful for conventional
gamma-camera imaging of SRIF receptor-positive
tumors and their
metastases. To evaluate the feasibility of positron emission tomography (PET) or SRIF receptor-positive
tumors deferoxamine (DFO) was conjugated to
octreotide via a succinyl linker to form a stable conjugate with the
gallium isotopes 67Ga and 68Ga. This new
octreotide analog,
SDZ 216-927, binds specifically and with high affinity to SRIF receptors in vitro (pKi = 8.94 +/- 0.06) and exhibits SRIF like
biological properties as demonstrated by the inhibition of
growth hormone (GH) release from cultured pituitary cells.
SDZ 216-927 was efficiently labelled with 67Ga without affecting high affinity binding to SRIF receptors. Biodistribution studies revealed that [67Ga]
SDZ 216-927 was stable in vivo and rapidly cleared from the circulation, as indicated by the low amount of 67Ga detected in the blood four hours post injection (p.i.). SRIF receptor-positive
tumors were clearly visualized 10 minutes p.i. in
tumor bearing rats. The specificity of
ligand binding in vivo was demonstrated i) by the high
tumor/non-
tumor ratio 4 hours p.i. (
tumor/blood 22.3:1,
tumor/muscle 64.5:1,
tumor/liver 4.0:1,
tumor/spleen 16.8:1) and ii) by a significantly lower uptake of radioactivity in the
tumor after pretreatment of
tumor bearing animals with an excess of unlabelled
SDZ 216-927.
SDZ 216-927, when labelled with the positron emitting
isotope 68Ga, clearly imaged SRIF receptor-positive
tumors using positron emission tomography (PET). Therefore quantitative SRIF receptor imaging with PET seems to be possible using this new
radiopharmaceutical.